Subscribe
6 May 2025NewsAmericasMarisa Woutersen

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

More on this story

Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

More features

Fed Circ refuses to stay Novartis feud with MSN over Entresto
Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute
‘It’s going to be very different’: INTA CEO shares London meeting plans